DOCSLIB.ORG

Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular Diabetes Care Volume 42, March 2019 349 COMMENTARY Therapeutic Inertia and the Legacy Kamlesh Khunti and Samuel Seidu of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes Diabetes Care 2019;42:349–351 | https://doi.org/10.2337/dci18-0030 Type 2 diabetes is characterized by a reduced costs and increased quality of significant cost avoidance of about continuous decline in b-cell function life (11). £340 million was apparent in the first with the resultant progressive loss of Besides patient-level characteristics 5 years, rising to about £5.5 billion after glycemic control over time (1). The such as multimorbidity and poor adher- 25 years of sustained improvement in hyperglycemic burden is associated ence to treatment recommendations, control. Reductions in microvascular with longer-term microvascular and clinical inertia has been suggested as complications were the main factors macrovascular complications. Early di- one key reason for not achieving glucose driving the cost savings, with 74% of agnosis and intensive glycemic control targets. The term “clinical inertia” in cost avoidance from prevention of renal has conclusively demonstrated a re- most instances has been used in relation disease in people with type 1 diabetes duction in microvascular complications to failure to advance therapy when ap- and 57% of cost avoidance from reduc- (2,3) and possibly macrovascular com- propriate to do so (12). However, the tions in foot ulcers, amputations, and plications over a long period of obser- definition of therapeutic inertia is now neuropathy in people with type 2 di- vation (4), the so-called legacy effect also accepted to reflect the failure to abetes (14). (5). Even though there have been im- de-intensify treatment when appropri- In the study in this issue of Diabetes provements in survival from cardiovas- ate to do so (12). A number of studies Care using routine real-world data to cular disease in the general population, have shown that therapeutic inertia is explore the concept of legacy effects people with type 2 diabetes remain associated with worse microvascular of tight glycemic control on complica- at increased risk of cardiovascular mor- and macrovascular outcomes. In a cohort tions of diabetes, Laiteerapong et al. (15) tality compared with matched popula- study of 105,477 patients, mean HbA1c focused on newly diagnosed patients tion control subjects (6). A very high was 8.1% (65 mmol/mol) at diagnosis, who had poor glycemic control and proportion of patients fail to reach the 22% remained under poor glycemic con- 10 years of survival. They demonstrated recommended glycemic targets for a trol over 2 years, and 26% never received that HbA1c levels $6.5% ($48 mmol/mol) considerable period of time after the intensive treatment. A delay in intensive for the first year after diagnosis were diagnosis of diabetes (7–9), thus lead- treatment by 1 year in conjunction with associated with worse outcomes. They ing to the complications. Guidelines for poor glycemic control significantly in- showed that there was a relative in- the treatment of patients with type 2 creased the risk of myocardial infarction, crease in mortality of 29% in patients diabetes suggest that tight glycemic heart failure, stroke, and composite car- with a dysglycemic burden of HbA1c 7% control (defined as glycated hemoglo- diovascular events (hazard ratio 1.62 to ,8% in the first year of diagnosis bin [HbA1c] ,7.0% [53 mmol/mol]) [95% CI 1.46–1.80]) (7). In another study compared with HbA1c maintained at should be maintained from diagnosis using a computer simulation model de- ,6.5%. This increase rose to 32% if through active titration of combina- signed to translate surrogate end points the dysglycemic legacy was HbA1c tions of antihyperglycemic medica- into long-term health and economic out- $9% in the first year of diagnosis. The tions and lifestyle modification, as comes (the IMS CORE Diabetes Model achievement of glycemic control after appropriate (10). Modeling studies [13]) in a representative cohort of adults diabetes diagnosis is therefore sufficient suggest that when this is done through with type 1 or type 2 diabetes from the to establish remedial long-term risk of an individualized approach, it leads to U.K. primary care patient database, complications (15). Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K. Corresponding author: Kamlesh Khunti, kk22@le.ac.uk © 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. See accompanying article, p. 416. 350 Commentary Diabetes Care Volume 42, March 2019 Laiteerapong et al. (15) assessed the instance, the analysis did not differenti- the study population was ethnically di- associations between HbA1c ,6.5% ate between patients with or without verse, the analysis could have been (,48 mmol/mol), 6.5% to ,7.0% (48 to prior cardiovascular disease. As the strengthened even more by examination ,53 mmol/mol), 7.0% to ,8.0% (53 to UKPDS recruited newly diagnosed pa- of the outcomes by different ethnicities ,64 mmol/mol), 8.0% to ,9.0% (64 tients, most of whom had no prevalent and levels of deprivation. In an observa- to ,75 mmol/mol), or $9.0% ($75 cardiovascular disease, it would have tional study of this nature, the influence mmol/mol) for different periods of early been more informative to explore pa- of many more confounding factors, exposure (0–1, 0–2, 0–3, 0–4, 0–5, 0–6, tients with and without prevalent car- known and unknown, cannot be com- and 0–7 years) to demonstrate the re- diovascular disease in the current study. pletely excluded. medial long-term legacy benefits. HbA1c In a recent analysis of 15 years of There is currently a lot of interest in real- levels of $6.5% in the first year of the follow-up results of the Veterans Affairs world evidence. The findings in this study early exposure period carried a higher Diabetes Trial (VADT), patients with (15) support evidence from randomized risk for microvascular and macrovascular established cardiovascular disease re- controlled trials for the need to intensify complications than HbA1c ,6.5% in the cruited in that study did not demonstrate blood glucose–lowering therapy in a first year of glycemic exposure. For ex- the legacy benefits (21) demonstrated in timely manner to ensure that the benefits ample, for HbA1c ,7%, the hazard ratio the UKPDS, although such benefits were of reduced blood glucose are realized. It was 1.24 (95% CI 1.06–1.37) (15). This is a demonstrated after 10 years (22). An- is expected that sustained reduced HbA1c generous span of the whole spectrum other limitation is the sole emphasis on levels over a long period of time, achieved of poor glycemic control and allows for the early sustained intensive glycemic through the confines of the strict proto- adequate evaluation of the effects of control. In real clinical practice, there are cols of randomized control trials, will be good early control on glycemic legacy. marked variations in care standards and associated with reduced microvascular The UK Prospective Diabetes Study patients’ self-management, thus result- and macrovascular events (Fig. 1). In (UKPDS) demonstrated the legacy ing in variation in HbA1c levels, which has addition to therapeutic inertia in glycemic effects of HbA1c reduction below 7% also been associated with poor outcomes control, recent studies have also revealed (3). Additionally, the American Diabe- (23). Also, even though this study is associations of long-term glycemic vari- tes Association–European Association dubbed a real-world study, 34,737 of ability of HbA1c with microvascular and for the Study of Diabetes position state- the eligible 44,763 patients were in- macrovascular control (23). The mecha- ment also recommended HbA1c targets cluded in the analysis. The strength of nism for this is not entirely certain, of 6.5% in newly diagnosed patients (10). real-world studies is the inclusion of but HbA1c variability has been shown There are a number of strengths to this patients with varying characteristics, to increase urinary excretion of 8-iso- study. It is a population-based study reminiscent of those in real clinical prac- prostaglandin F2a, a marker of oxidative with a large number (34,737) of partic- tice, as opposed to the refined selection stress (25). Wide variations of HbA1c could ipants included in the analysis. The an- of patients in randomized controlled reflect poor adherence to therapeutic and alytical methodology was very thorough, trials (24). In this instance, it is unclear lifestyle interventions, a more compli- capturing not just the raised levels of whether the remaining 22.4% of the cated clinical course, or a subpar organi- HbA1c but also the periods of dysglycemic patients excluded would have behaved zational process of diabetes care. Figure 1 exposures. Another strength of this study differently. Therefore, the exclusion of demonstrates the theoretical adverse ef- was that it included an ethnically diverse such a large proportion of the study fects of both a legacy of dysglycemia as a population. Most studies on this subject population limits the generalizability of result of therapeutic inertia (potentially are usually conducted in predominantly the results of this study. Finally, although avoided through the confines of strict Caucasian populations, thus making the results less generalizable to other pop- ulations. The study also highlights in its analysis all diabetes complications, in- cluding microvascular complications, macrovascular complications, and mor- tality. Previous publications on this sub- ject have usually just focused on macrovascular (7) or microvascular com- plications (16) or surrogate cardiovascu- lar risk factors.
Load more
Loading...
Loading...
Loading...

—— Preview end. ——

Recommended publications
  • Metformin Should Not Be Used to Treat Prediabetes
    Diabetes Care Volume 43, September 2020 1983 Metformin Should Not Be Used to Mayer B. Davidson Treat Prediabetes – Diabetes Care 2020;43:1983 1987 | https://doi.org/10.2337/dc19-2221 PERSPECTIVES IN CARE Based on the results of the Diabetes Prevention Program Outcomes Study (DPPOS), in which metformin significantly decreased the development of diabetes in individuals with baseline fasting plasma glucose (FPG) concentrations of 110–125vs. 100–109 mg/dL (6.1–6.9 vs. 5.6–6.0 mmol/L) and A1C levels 6.0–6.4% (42–46 mmol/ mol) vs. <6.0% and in women with a history of gestational diabetes mellitus, it has been suggested that metformin should be used to treat people with prediabetes. Since the association between prediabetes and cardiovascular disease is due to the associated nonglycemic risk factors in people with prediabetes, not to the slightly increased glycemia, the only reason to treat with metformin is to delay or prevent the development of diabetes. There are three reasons not to do so. First, approximately two-thirds of people with prediabetes do not develop diabetes, even after many years. Second, approximately one-third of people with prediabetes return to normal glucose regulation. Third, people who meet the glycemic criteria for prediabetes are not at risk for the microvascular complications of diabetes and thus metformin treatment will not affect this important outcome. Why put people who are not at risk for the microvascular complications of diabetes on a drug (possibly for the rest of their lives) that has no immediate advantage except to lower subdiabetes glycemia to even lower levels? Rather, individuals at the highest risk for developing diabetesdi.e., those with FPG concentrations of 110–125 mg/dL (6.1– 6.9 mmol/L) or A1C levels of 6.0–6.4% (42–46 mmol/mol) or women with a history of gestational diabetes mellitusdshould be followed closely and metformin im- mediately introduced only when they are diagnosed with diabetes.
    [Show full text]
  • Dysglycemia and the Importance of Nutrition Therapy Rachel A
    Hospital Dysglycemia and the Importance of Nutrition Therapy Rachel A. Johnson, RD Scientific and Medical Affairs, Abbott Nutrition Columbus, Ohio, USA INTRODUCTION As the global diabetes epidemic continues to grow, so does the number of hospitalized patients with diabetes and hyperglycemia. Dysglycemia, in the form of hyperglycemia, hypoglycemia and glycemic variability, is common and associated with poor clinical outcomes in hospitalized patients. However, observational and randomized controlled studies demonstrate that better glycemic control improves outcomes, including lower rates of hospital complications. The development of effective strategies, including nutrition strategies, is imperative for effective glycemic management in the hospitalized patient. HOSPITAL DYSGLYCEMIA: A MARKER FOR QUALITY OF CARE Dysglycemia, which can be an indicator of poor quality of care, increases the risk for adverse outcomes in surgical patients and common clinical conditions including stroke and critical illness. For example, acute hyperglycemia predicts increased risk of in-hospital mortality after ischemic stroke and increases the risk of poor functional recovery.1 In critically ill patients, increased glycemic variability is an independent risk factor for mortality, increasing the risk by 2- to 5-fold.2,3 In surgical patients, perioperative hyperglycemia increases the incidence of systemic blood infections, surgical site infections, acute renal failure, and postoperative mortality.4-7 Increased Acute Mortality Renal Surgical Site Failure Infection
    [Show full text]
  • Philippine Practice Guidelines on the Diagnosis and Management of Diabetes Mellitus
    Fall 08 Philippine Diabetes Association, Inc. Philippine Society of Endocrinology and Metabolism Institute for Studies on Diabetes Foundation, Inc. Philippine Center for Diabetes Education Foundation, Inc. UNITE FOR DIABETES PHILIPPINES Philippine Practice Guidelines for the Diagnosis and Management of Diabetes: Part 1- Screening & Diagnosis Philippine Practice Guidelines for the Management of Diabetes Part 1: Screening and Diagnosis Part 1- Screening & Diagnosis Document Title] Unite for Diabetes Philippines 2011 2 Philippine Practice Guidelines on the Diagnosis and Management of Diabetes Mellitus A Project of UNITE FOR Diabetes Philippines: A Coalition of Organizations Caring for Individuals with Diabetes Mellitus Diabetes Philippines (Formerly Philippine Diabetes Association) Institute for Studies on Diabetes Foundation, Inc (ISDFI) Philippine Center for Diabetes Education Foundation (PCDEF) Philippine Society of Endocrinology and Metabolism (PSEM) Technical Review Committee Members: Dr. Cecilia Jimeno – Head Dr. Lorna Abad Dr. Aimee Andag-Silva Dr. Elaine Cunanan Dr. Richard Elwynn Fernando Dr. Mia Fojas Dr. Iris Thiele Isip-Tan Dr. Leilani Mercado-Asis Administrative Panel: Dr. Maria Honolina Gomez (PCDEF) Dr. Gabriel V. Jasul, Jr (PSEM) Dr. Leorino M. Sobrepeña (ISDF) Dr. Tommy Ty Willing (Diabetes Philippines) (Consensus) Panel of Experts: Associations/Agencies Representative 1. Dr. Susan Yu-Gan 2. Sanirose S. Orbeta, MSRD, FADA Diabetes Philippines 3. Dr. Joy C. Fontanilla 3 Associations/Agencies Representative 4. Dr. Jose Carlos Miranda Diabetes Center (Philippine Center for 5. Dr. Jimmy Aragon Diabetes Education Foundation) 6. Dr. Augusto D. Litonjua 7. Dr. Carolyn Narvacan-Montano Institute for Studies on Diabetes Foundation, 8. Dr. Grace K. Delos Santos Inc (ISDFI) 9. Dr. Rima Tan 10. Dr. Ernesto Ang Philippine Society of Endocrinology and 11.
    [Show full text]
  • The Dysglycemia Diet
    The Dysglycemia Diet To more fully understand why we have designed this program, it is helpful to know a little about the biochemistry of blood sugar. Blood sugar, or serum glucose, is often measured with routine blood work at the doctor’s office. Glucose is the basic fuel all cells in your body use to make energy. Although it is measured in the blood, glucose can only be put to work and transformed into energy once it is in the cells, not when it is circulating in the bloodstream. It might be helpful to consider the bloodstream as the highway, and the cells as the factory. Glucose is the raw material that must be transported along the highway to the factory to be put to use. In an optimal state, the body maintains the blood glucose level in a fairly narrow range. The range is neither too low (which is called hypoglycemia), nor too high (called hyperglycemia). Stability of blood sugar is important, because imbalances, particularly elevated levels, can cause serious health problems. Chronically elevated blood glucose levels result in the development of diabetes, which can lead to severe complications such as blindness, kidney failure, and heart disease. To remain healthy, the body does all it can to maintain blood sugar levels within this normal optimal range. It achieves this stability through the secretion of a hormone called insulin. Insulin is the vehicle that allows glucose to be transported from the blood stream into the cells. A complete inability to secrete insulin, which occurs in juvenile onset diabetes, drastically increases glucose levels in the bloodstream.
    [Show full text]
  • Increased Frequency of Diabetes and Other Forms of Dysglycemia in The
    COMPARE AND PCB-RISK PROJECT: INTEGRATED RISK ASSESSMENT OF PCBS, THEIR METABOLITES AND HALOGENATED FLAME RETARDANTS Increased frequency of diabetes and other forms of dysglycemia in the population of specific areas of eastern Slovakia chronically exposed to contamination with polychlorinated biphenyls (PCB). Zofia Radikova1, Juraj Koska1, Lucia Ksinantova1, Richard Imrich1, Anton Kocan2, Jan Petrik2, Miroslava Huckova1, Ladislava Wsolova2, Pavel Langer1, Tomas Trnovec2, Elena Sebokova1, Iwar Klimes1 ''Institute of Experimental Endocrinology, SAS, Bratislava, Slovakia 2Research Base of the Slovak Health University - IPCM, Bratislava, Slovakia Introduction Some studies suggest that exposure to organochlorine pollutants may affect glucose metabolism and insulin secretion and action 1-5. Considerable pollution of water, soil and food chain in Eastern Slovakia was caused by a chemical factory, which was manufacturing PCBs in 1959-1985. The aim of the present preliminary evaluation of data obtained within the EC project PCBRISK was to search for further interrelations between long-term organochlorine pollution and disturbances in glucose homeostasis in large cohorts of population from three districts of Eastern Slovakia. Materials and Methods Population: a total of 2050 adults, 835 males (44.9 ± 0.4 years, BMI = 27.4 ± 0.1 kg/m2) and 1215 females (44.7 ± 0.3 years, BMI = 26.6 ± 0.1 kg/m2) from three districts of Eastern Slovakia were examined. Some data were not obtained from negligible number of subjects due to technical reasons. Baseline samples and oral glucose tolerance test: Fasting baseline blood samples were obtained from all 2050 participating subjects. A standard oral glucose tolerance test (75g glucose) was performed in 1222 willing subjects without previous evidence of diabetes or other dysglycemia.
    [Show full text]
  • Pancreatogenic Type 3C Diabetes: Underestimated, Underappreciated and Poorly Managed
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #163 NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #163 Carol Rees Parrish, M.S., R.D., Series Editor Pancreatogenic Type 3c Diabetes: Underestimated, Underappreciated and Poorly Managed Sinead N. Duggan Kevin C. Conlon Type 3c diabetes, also known as pancreatogenic diabetes, refers to diabetes resulting from pancreatic disease, including pancreatitis, cystic fibrosis and pancreatic cancer. It is difficult to diagnose, and for many, management is challenging due to erratic swings from hypoglycemia to hyperglycemia caused by metabolic abnormalities due to pancreatic tissue damage. This review aims to describe the disease along with its characteristics, diagnosis, complications, and management. CLINICAL CASE 1 42 year old male with an eight-year history regarding adequate dietary intake, prescribed oral of alcohol-induced chronic pancreatitis was nutritional supplements, and counselled on adequate Aadmitted from the ER. His current weight was and appropriate usage of PERT. Blood work revealed 61Kg as opposed to his usual weight of 67Kg; his low levels of serum vitamins (25 OHD, vitamin E and appearance was cachectic. He reported abdominal pain, vitamin A), normal fasting glucose and HbA1c. He intermittent diarrhea/steatorrhea along with periods of was discharged after 3 days once he was established constipation, cramping, flatulence and poor appetite. He on adequate oral diet, micronutrient supplementation, was not compliant with prescribed pancreatic enzyme PERT, and his pain medication had been adjusted. He replacement therapy (PERT), was still abusing alcohol, was readmitted three weeks later with dehydration, and was a heavy smoker for many years. He took fatigue, excess thirst and blurred vision. Fasting glucose opiates for relief of chronic, constant abdominal pain.
    [Show full text]
  • Dysglycemia and Dyslipidemia Models in Nonhuman Primates:Part
    abetes & Di M f e o t a l b a o Wang et al., J Diabetes Metab 2015, S13 n l r i s u m o DOI: 10.4172/2155-6156.S13-010 J Journal of Diabetes and Metabolism ISSN: 2155-6156 Research Article Open Access Dysglycemia and Dyslipidemia Models in Nonhuman Primates: Part I. Model of Naturally Occurring Diabetes Xiaoli Wang, Bingdi Wang, Guofeng Sun, Jing Wu, Yongqiang Liu, Yixin (Jim) Wang and Yong-Fu Xiao* Cardiovascular and Metabolic Disease Research, Crown Bioscience, Inc., 6 Beijing West Road, Taicang Economic Development Area, Taicang, Jiangsu Province, China Abstract Insulin-resistant diabetes (Type 2 diabetes mellitus, T2DM) is one of the main comorbidities of obesity and is the most common form of diabetes. T2DM and obesity dynamically influence each other and often escalate patients’ other health issues. Cardiovascular, renal and other health consequences of obesity and diabetes have been studied for several decades. However, the underlying precise mechanisms and interactions of obesity and insulin-resistant diabetes have yet to be elucidated further. It has been recognized that sustained greater energy intake than expenditure is the main cause of obesity that can potentially lead to insulin resistance and diabetes due to excessive fat accumulation. To better understand the pathophysiology of human obesity and diabetes, nonhuman primate (NHP) models have been used for research to delineate molecular and cellular mechanisms because of the similarity of the metabolic diseases between NHP and humans. Also, NHP models have been well used for testing new novel therapies, which provides critical pre-clinic information for drug discovery.
    [Show full text]
  • Do We Need to Treat Impaired Glucose Tolerance and Impaired Fasting Glucose?
    International Journal of Diabetes Mellitus 1 (2009) 22–25 Contents lists available at ScienceDirect International Journal of Diabetes Mellitus journal homepage: ees.elsevier.com/locate/ijdm Review Approach to dysglycemia: Do we need to treat impaired glucose tolerance and impaired fasting glucose? Mousa A. Abujbara, Kamel M. Ajlouni * National Center for Diabetes, Endocrinology and Genetics, P.O. Box 13165 Amman 11942, Jordan article info abstract Article history: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are not only a surrogate for the state Received 7 October 2008 of insulin resistance but are also associated with the microvascular and macrovascular complications tra- Accepted 7 November 2008 ditionally linked to diabetes. They predict an increased risk for death and morbidity due to cardiovascular disease. There is growing evidence that early detection of this state of ‘‘pre-diabetes” enables us to limit these recognized complications and perhaps to halt the progression to diabetes. For all pre-diabetes patients’ life style modifications, emphasizing modest weight loss & moderate physical activity are strongly rec- ommended. Pharmacological intervention may also be necessary. Many studies have shown several drugs, both antidiabetic and nonhypoglycemic agents to be useful. If pharmacological treatment is required, Metformin is considered the first choice because of its safety, tolerability, efficacy and low cost. Ó 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd. All rights reserved. 1. Introduction Between 1997 and 2006, eight major clinical trials examined whether lifestyle or pharmacologic interventions would prevent Diabetes and its complications are a growing concern world- or delay the development of diabetes in populations with IFG wide.
    [Show full text]
  • Undetected Dysglycemia an Important Risk Factor For
    Diabetes Care 1 Anna Norhammar,1,2 Barbro Kjellstrom,¨ 1 Undetected Dysglycemia an Natalie Habib,1 Anders Gustafsson,3 Bjorn¨ Klinge,3,4 Ake˚ Nygren,5 Per Nasman,¨ 6 Important Risk Factor for Two Elisabet Svenungsson,1 and Lars Ryden´ 1 Common Diseases Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study https://doi.org/10.2337/dc19-0018 OBJECTIVE Information on the relationship among dysglycemia (prediabetes or diabetes), myocardial infarction (MI), and periodontitis (PD) is limited. This study tests the hypothesis that undetected dysglycemia is associated with both conditions. RESEARCH DESIGN AND METHODS The PAROKRANK (Periodontitis and Its Relation to Coronary Artery Disease) study included 805 patients with a first MI and 805 matched control subjects. All participants without diabetes (91%) were examined with an oral glucose tolerance CARDIOVASCULAR AND METABOLIC RISK test. Abnormal glucose tolerance ([AGT] = impaired glucose tolerance or diabetes) was categorized according to the World Health Organization). Periodontal status 1Department of Medicine K2, Karolinska Institu- was categorized from dental X-rays as healthy (‡80% remaining alveolar bone tet, Stockholm, Sweden height), moderate (79–66%), or severe (<66%) PD. Odds ratios (ORs) and 95% CIs 2Capio St. Gorans¨ hospital, Stockholm, Sweden 3 were calculated by logistic regression, and were adjusted for age, sex, smoking, Department of Dental Medicine, Karolinska In- stitutet, Stockholm, Sweden education, marital status, and explored associated risks of dysglycemia to PD and 4Faculty of Odontology, Department of Periodon- MI, respectively. tology, Malmo¨ University, Malmo,¨ Sweden 5Department of Clinical Sciences Danderyds Hos- RESULTS pital, Karolinska Institutet, Stockholm, Sweden 6 AGT was more common in patients than in control subjects (32% vs.
    [Show full text]
  • Screening for Prediabetes and Type 2 Diabetes in Dental Offices
    Journal of Public Health Dentistry . ISSN 0022-4006 Screening for prediabetes and type 2 diabetes in dental offices William H. Herman, MD, MPH1,2; George W. Taylor, DMD, MPH, DrPH3; Jed J. Jacobson, DDS, MS, MPH4; Ray Burke, MA1; Morton B. Brown, PhD5 1 Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA 2 Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA 3 School of Dentistry, University of Michigan, Ann Arbor, MI, USA 4 Delta Dental of Michigan, Ohio, and Indiana, Lansing, MI, USA 5 Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA Keywords Abstract screening; dental office; prediabetes; diabetes; periodontal disease; epidemiology. Objectives: Most Americans see dentists at least once a year. Chair-side screening and referral may improve diagnosis of prediabetes and diabetes. In this study, we Correspondence developed a multivariate model to screen for dysglycemia (prediabetes and diabetes Dr. William H. Herman, University of Michigan, defined as HbA1c ≥5.7 percent) using information readily available to dentists and 1000 Wall Street, Room 6108 / SPC 5714, Ann Arbor, MI 48105-1912. Tel.: 734-936-8279; assessed the prevalence of dysglycemia in general dental practices. Fax: 734-647-2307; e-mail: Methods: We recruited 1,033 adults ≥30 years of age without histories of diabetes wherman@umich.edu. William H. Herman from 13 general dental practices.A sample of 181 participants selected on the basis of and Ray Burke are with the Department random capillary glucose levels and periodontal status underwent definitive diag- of Internal Medicine, University of Michigan. nostic testing with hemoglobin A1c.
    [Show full text]
  • Impact of Insulin and Metformin Versus Metformin Alone on Β-Cell
    Diabetes Care Volume 41, August 2018 1717 Impact of Insulin and Metformin The RISE Consortium* Versus Metformin Alone on b-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes Diabetes Care 2018;41:1717–1725 | https://doi.org/10.2337/dc18-0787 OBJECTIVE Pediatric type 2 diabetes prevalence is increasing, with b-cell dysfunction key in its pathogenesis. The RISE Pediatric Medication Study compared two approachesd glargine followed by metformin and metformin alonedin preserving or improving b-cell function in youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes during and after therapy withdrawal. RESEARCH DESIGN AND METHODS Ninety-one pubertal, overweight/obese 10–19-year-old youth with IGT (60%) PATHOPHYSIOLOGY/COMPLICATIONS or type 2 diabetes of <6 months duration (40%) were randomized to either 3 months of insulin glargine with a target glucose of 4.4–5.0 mmol/L followed by 9 months of metformin or to 12 months of metformin alone. b-Cell function (insulin sensitivity paired with b-cell responses) was assessed by hyperglycemic clamp at baseline, 12 months (on treatment), and 15 months (3 months off treatment). RESULTS No significant differences were observed between treatment groups at baseline, RISE Coordinating Center, Rockville, MD 12 months, or 15 months in b-cell function, BMI percentile, HbA1c, fasting glucose, Corresponding author: Sharon L. Edelstein, rise@ or oral glucose tolerance test 2-h glucose results. In both treatment groups, clamp- bsc.gwu.edu. measured b-cell function was significantly lower at 12 and 15 months versus Received 10 April 2018 and accepted 13 May 2018.
    [Show full text]
  • Basal Glucose Can Be Controlled, but the Prandial Problem Persistsdit's
    Diabetes Care Volume 40, March 2017 291 Basal Glucose Can Be Controlled, Matthew C. Riddle but the Prandial Problem PersistsdIt’stheNextTarget! PERSPECTIVES IN CARE Diabetes Care 2017;40:291–300 | DOI: 10.2337/dc16-2380 Both basal and postprandial elevations contribute to the hyperglycemic exposure of diabetes, but current therapies are mainly effective in controlling the basal compo- nent. Inability to control postprandial hyperglycemia limits success in maintaining overall glycemic control beyond the first 5 to 10 years after diagnosis, and it is also related to the weight gain that is common during insulin therapy. The “prandial problem”dcomprising abnormalities of glucose and other metabolites, weight gain, and risk of hypoglycemiaddeserves more attention. Several approaches to prandial abnormalities have recently been studied, but the patient populations for which they are best suited and the best ways of using them remain incompletely defined. Encouragingly, several proof-of-concept studies suggest that short-acting glucagon- like peptide 1 agonists or the amylin agonist pramlintide can be very effective in controlling postprandial hyperglycemia in type 2 diabetes in specific settings. This article reviews these topics and proposes that a greater proportion of available resources be directed to basic and clinical research on the prandial problem. Widespread self-testing of blood glucose and, more recently, continuous glucose mon- itoring (CGM) have drawn attention to the daily patterns of blood glucose in both type 1 and type 2 diabetes. Seeing these patterns has allowed separate consideration of fasting (basal) hyperglycemia and after-meal (postprandial) increments of glucose above basal levels. In entirely healthy individuals, fasting plasma glucose is rarely .100 mg/dL (5.5 mmol/L).
    [Show full text]